Back to top

LACOG 0221 – BRAVE

  /    /  LACOG 0221 – BRAVE

Real-World Data on First-line Treatment of Hormone Receptor-positive, HER2-negative, Metastatic Breast Cancer in Brazil (LACOG 0221) – BRAVE Study

Type of Study: Epidemiological

Sponsor / Support: LACOG, GBECAM

Primary Objectives: Describe the first-line treatment of hormone receptor-positive, HER2- negative metastatic breast cancer in Brazil.

Design: This is an observational, retrospective cohort study.

Sample Size: 300 patients

Principal Investigator: Gustavo Werutsky

Countries LATAM: Brazil

Clinicaltrials.gov Identifier: NCT05034393 

The study is open to patients participation in the following research sites:

CPO-RS - Centro de Pesquisa em Oncologia / Porto Alegre / RS / Brazil

CRIO - Centro Regional Integrado de Oncologia / Fortaleza / CE / Brazil

Hospital Jardim Amalia - HINJA / Volta Redonda / RJ / Brazil

CEPESG - Instituto Devita Oncologia e Hematologia / Caxias do Sul / RS / Brazil

Instituto de Hematologia e Oncologia de Curitiba / Curitiba / PR / Brazil

INCA-RJ / Rio de Janeiro / RJ / Brazil

CPO-PA / João Pessoa / PA / Brazil

Centro Paraibano De Oncologia / João Pessoa / PB / Brazil

Centro Integrado De Pesquisa Do Amazonas / Manaus / AM / Brazil

Hospital Moinhos de Vento / Porto Alegre / RS / Brazil

CLION - BA / Salvador / BA / Brazil

Instituto do Câncer Brasil - MS / Três Lagoas / MS / Brazil

Instituto de Gestão Estratégica em Saúde-DF / Brasília / DF / Brazil